TY - JOUR
T1 - Peritoneal carcinomatosis
T2 - Cytoreductive surgery and HIPEC-overview and basics
AU - Brcher, Björn L.D.M.
AU - Piso, Pompiliu
AU - Verwaal, Vic
AU - Esquivel, Jesus
AU - Derraco, Marcello
AU - Yonemura, Yutaka
AU - Gonzalez-Moreno, Santiago
AU - Pelz, Jörg
AU - Königsrainer, Alfred
AU - Ströhlein, Michael
AU - Levine, Edward A.
AU - Morris, David
AU - Bartlett, David
AU - Glehen, Olivier
AU - Garofalo, Alfredo
AU - Nissan, Aviram
PY - 2012/3
Y1 - 2012/3
N2 - Tumor involvement of the peritoneumperitoneal carcinomatosisis a heterogeneous form of cancer that had been generally regarded as a sign of systemic tumor disease and as a terminal condition. The multimodal treatment approach for patients with peritoneal carcinomatosis, which had been conceived and developed, consists of what is known as cytoreductive surgery, followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Depending on the tumor mass as assessed intraoperatively and the histopathological differentiation, patients who undergo cytoreductive surgery and HIPEC have a significant survival benefit. Mean increases in the survival period ranging from six months to up to four years have now been reported. In view of the substantial logistic effort and the extent of the surgery involved, this treatment approach represents a major challenge both for patients and for surgical oncologists, as well as for the members of the overall interdisciplinary structure required, which includes oncology, anesthesiology and intensive care, psycho-oncology, and patient management. The surgical procedures alone may take 814 hr. The present paper provides an overview of the basis for the approach and the use of specialized classifications and quantitative prognostic indicators.
AB - Tumor involvement of the peritoneumperitoneal carcinomatosisis a heterogeneous form of cancer that had been generally regarded as a sign of systemic tumor disease and as a terminal condition. The multimodal treatment approach for patients with peritoneal carcinomatosis, which had been conceived and developed, consists of what is known as cytoreductive surgery, followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Depending on the tumor mass as assessed intraoperatively and the histopathological differentiation, patients who undergo cytoreductive surgery and HIPEC have a significant survival benefit. Mean increases in the survival period ranging from six months to up to four years have now been reported. In view of the substantial logistic effort and the extent of the surgery involved, this treatment approach represents a major challenge both for patients and for surgical oncologists, as well as for the members of the overall interdisciplinary structure required, which includes oncology, anesthesiology and intensive care, psycho-oncology, and patient management. The surgical procedures alone may take 814 hr. The present paper provides an overview of the basis for the approach and the use of specialized classifications and quantitative prognostic indicators.
KW - Colon cancer
KW - Gastric cancer
KW - HIPEC
KW - Peritoneal carcinomatosis
KW - Pseudomyxoma
UR - http://www.scopus.com/inward/record.url?scp=84857586698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857586698&partnerID=8YFLogxK
U2 - 10.3109/07357907.2012.654871
DO - 10.3109/07357907.2012.654871
M3 - Review article
C2 - 22360361
AN - SCOPUS:84857586698
SN - 0735-7907
VL - 30
SP - 209
EP - 224
JO - Cancer Investigation
JF - Cancer Investigation
IS - 3
ER -